Compare · CNC vs CNTG
CNC vs CNTG
Side-by-side comparison of Centene Corporation (CNC) and Centogene N.V. (CNTG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and CNTG operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $31.31B, about 335.7x CNTG ($93.3M).
- CNC has hit the wire 3 times in the past 4 weeks while CNTG has been quiet.
- CNC has more recent analyst coverage (25 ratings vs 1 for CNTG).
- Company
- Centene Corporation
- Centogene N.V.
- Price
- $63.40-0.51%
- $0.56+86.47%
- Market cap
- $31.31B
- $93.3M
- 1M return
- +0.69%
- -
- 1Y return
- +136.02%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 1
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Latest CNC
- Director Tyler Lauren M was granted 3,155 shares, increasing direct ownership by 5,172% to 3,216 units (SEC Form 4)
- CENTENE CORPORATION TO HOST 2026 SECOND QUARTER FINANCIAL RESULTS EARNINGS CALL
- CENTENE SUBSIDIARY MERIDIAN HEALTH PLAN OF ILLINOIS AWARDED ILLINOIS MEDICAID CONTRACT
- Director Tyler Lauren M was granted 61 shares (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 465 shares, increasing direct ownership by 2% to 25,213 units (SEC Form 4)
- Director Tanji Kenneth was granted 581 shares, increasing direct ownership by 5% to 12,490 units (SEC Form 4)
- Director Eppinger Frederick H was granted 833 shares, increasing direct ownership by 0.23% to 369,538 units (SEC Form 4)
- Director Coughlin Christopher J was granted 562 shares, increasing direct ownership by 3% to 18,711 units (SEC Form 4)
- Health Net Providing Special Assistance to Members and Providers Affected by Palos Warehouse Fire in Los Angeles
- RBC Capital Mkts initiated coverage on Centene with a new price target
Latest CNTG
- CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
- CENTOGENE Announces Voting Results of Extraordinary General Meeting
- CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
- CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
- SEC Form 6-K filed by Centogene N.V.
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Receives Delisting Notice From Nasdaq
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
- Centogene shares are trading higher after the company signed a Memorandum of Understanding with C-Path for collaboration in lysosomal disease research and drug development.